These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
107 related articles for article (PubMed ID: 14593967)
1. [The location of components of fibrinolytic system in laryngeal cancer]. Sierko E; Tokajuk P; Zimnoch L; Wojtukiewicz MZ Pol Merkur Lekarski; 2003 Jul; 15(85):81-5. PubMed ID: 14593967 [TBL] [Abstract][Full Text] [Related]
2. Occurrence of components of fibrinolytic pathways in situ in laryngeal cancer. Wojtukiewicz MZ; Sierko E; Zacharski LR; Rózanska-Kudelska M; Zimnoch L Semin Thromb Hemost; 2003 Jun; 29(3):317-20. PubMed ID: 12888936 [TBL] [Abstract][Full Text] [Related]
3. Comparative study of the activity of high and low molecular weight urokinase in the presence of fibrin. Samama M; Castel M; Matsuo O; Hoylaerts M; Lijnen HR Thromb Haemost; 1982 Feb; 47(1):36-40. PubMed ID: 7041325 [TBL] [Abstract][Full Text] [Related]
4. The urokinase-system in tumor tissue stroma of the breast and breast cancer cell invasion. Hildenbrand R; Schaaf A Int J Oncol; 2009 Jan; 34(1):15-23. PubMed ID: 19082473 [TBL] [Abstract][Full Text] [Related]
5. Comparison of the in vitro fibrinolytic activities of low and high molecular weight single-chain urokinase-type plasminogen activator. de Munk GA; Groeneveld E; Rijken DC Thromb Haemost; 1993 Sep; 70(3):481-5. PubMed ID: 8259553 [TBL] [Abstract][Full Text] [Related]
6. Expression of fibrinolysis activators and their inhibitor in neointima of polyester vascular grafts. Kowalewski R; Zimnoch L; Wojtukiewicz MZ; Glowinski J; Glowinski S Biomaterials; 2004 Dec; 25(28):5987-93. PubMed ID: 15183613 [TBL] [Abstract][Full Text] [Related]
7. Localization of plasminogen activators and their inhibitor in squamous cell carcinomas of the head and neck. Yasuda T; Sakata Y; Kitamura K; Morita M; Ishida T Head Neck; 1997 Oct; 19(7):611-6. PubMed ID: 9323150 [TBL] [Abstract][Full Text] [Related]
8. Expression of urokinase-type plasminogen activator, urokinase-type plasminogen activator receptor and plasminogen activator inhibitors in patients with renal cell carcinoma: correlation with tumor associated macrophage and prognosis. Ohba K; Miyata Y; Kanda S; Koga S; Hayashi T; Kanetake H J Urol; 2005 Aug; 174(2):461-5. PubMed ID: 16006865 [TBL] [Abstract][Full Text] [Related]
9. The urokinase-type plasminogen activator, its receptor and u-PA inhibitor type-1 affect in vitro growth and invasion of Kaposi's sarcoma and capillary endothelial cells: role of HIV-Tat protein. Margheri F; D'Alessio S; Serratì S; Pucci M; Del Rosso A; Benelli R; Ferrari N; Noonan DM; Albini A; Fibbi G; Del Rosso M Int J Oncol; 2005 Jul; 27(1):223-35. PubMed ID: 15942664 [TBL] [Abstract][Full Text] [Related]
10. [D-dimer and plasminogen activator of the urokinase type: personal experiences with breast cancer]. Neises M; Schäfer T; Strittmatter HJ; Wischnik A; Dettmar P; Melchert F Geburtshilfe Frauenheilkd; 1993 Jul; 53(7):455-60. PubMed ID: 8370485 [TBL] [Abstract][Full Text] [Related]
12. Urokinase system expression in gastric carcinoma: prognostic impact in an independent patient series and first evidence of predictive value in preoperative biopsy and intestinal metaplasia specimens. Beyer BC; Heiss MM; Simon EH; Gruetzner KU; Babic R; Jauch KW; Schildberg FW; Allgayer H Cancer; 2006 Mar; 106(5):1026-35. PubMed ID: 16435385 [TBL] [Abstract][Full Text] [Related]
13. Quantitative RT-PCR assays for the determination of urokinase-type plasminogen activator and plasminogen activator inhibitor type 1 mRNA in primary tumor tissue of breast cancer patients: comparison to antigen quantification by ELISA. Biermann JC; Holzscheiter L; Kotzsch M; Luther T; Kiechle-Bahat M; Sweep FC; Span PN; Schmitt M; Magdolen V Int J Mol Med; 2008 Feb; 21(2):251-9. PubMed ID: 18204793 [TBL] [Abstract][Full Text] [Related]
14. [The relationship between the activation of ERK and the up-regulation of uPA in laryngeal squamous cell carcinoma]. Wang DW; Wang D; Wang Y; Ren Z Lin Chuang Er Bi Yan Hou Tou Jing Wai Ke Za Zhi; 2007 May; 21(9):390-3. PubMed ID: 17634019 [TBL] [Abstract][Full Text] [Related]
15. Effects of hypoxia and reoxygenation on the expression levels of the urokinase-type plasminogen activator, its inhibitor plasminogen activator inhibitor type-1 and the urokinase-type plasminogen activator receptor in human head and neck tumour cells. Sprague LD; Tomaso H; Mengele K; Schilling D; Bayer C; Stadler P; Schmitt M; Molls M Oncol Rep; 2007 May; 17(5):1259-68. PubMed ID: 17390074 [TBL] [Abstract][Full Text] [Related]
16. Galectin-3 upregulation during tumor progression in head and neck cancer. Saussez S; Decaestecker C; Mahillon V; Cludts S; Capouillez A; Chevalier D; Vet HK; André S; Toubeau G; Leroy X; Gabius HJ Laryngoscope; 2008 Sep; 118(9):1583-90. PubMed ID: 18677282 [TBL] [Abstract][Full Text] [Related]
18. Plasminogen activators in human xenografted oro-pharyngeal squamous cell carcinomas. Björlin G; Ljungnér H; Wennerberg J; Astedt B Acta Otolaryngol; 1987; 104(5-6):568-72. PubMed ID: 3434279 [TBL] [Abstract][Full Text] [Related]
19. Expression of plasminogen activator inhibitors type 1 and type 3 and urokinase plasminogen activator protein and mRNA in breast cancer. Castelló R; Landete JM; España F; Vázquez C; Fuster C; Almenar SM; Ramón LA; Radtke KP; Estellés A Thromb Res; 2007; 120(5):753-62. PubMed ID: 17258797 [TBL] [Abstract][Full Text] [Related]
20. Cell cycle proteins in laryngeal cancer: role in proliferation and prognosis. Peschos D; Stefanou D; Vougiouklakis T; Assimakopoulos DA; Agnantis NJ J Exp Clin Cancer Res; 2005 Sep; 24(3):431-7. PubMed ID: 16270530 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]